DK0805807T3 - 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-(1)-benzopyran til behandling af proliferative sygdomme - Google Patents

2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-(1)-benzopyran til behandling af proliferative sygdomme

Info

Publication number
DK0805807T3
DK0805807T3 DK95940839T DK95940839T DK0805807T3 DK 0805807 T3 DK0805807 T3 DK 0805807T3 DK 95940839 T DK95940839 T DK 95940839T DK 95940839 T DK95940839 T DK 95940839T DK 0805807 T3 DK0805807 T3 DK 0805807T3
Authority
DK
Denmark
Prior art keywords
benzopyran
methoxyphenyl
oxo
amino
proliferative diseases
Prior art date
Application number
DK95940839T
Other languages
English (en)
Inventor
James Bridges Alexander
Robert Saltiel Alan
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of DK0805807T3 publication Critical patent/DK0805807T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK95940839T 1995-01-24 1995-11-27 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-(1)-benzopyran til behandling af proliferative sygdomme DK0805807T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/378,131 US5525625A (en) 1995-01-24 1995-01-24 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
PCT/US1995/015373 WO1996022985A1 (en) 1995-01-24 1995-11-27 2-(2-amino-3-methoxyphenyl)-4-oxo-4h-[1]benzopyran for treating proliferative disorders

Publications (1)

Publication Number Publication Date
DK0805807T3 true DK0805807T3 (da) 2000-01-17

Family

ID=23491857

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95940839T DK0805807T3 (da) 1995-01-24 1995-11-27 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-(1)-benzopyran til behandling af proliferative sygdomme

Country Status (12)

Country Link
US (1) US5525625A (da)
EP (1) EP0805807B1 (da)
JP (1) JPH10512878A (da)
AT (1) ATE181913T1 (da)
CA (1) CA2208075A1 (da)
DE (1) DE69510696T2 (da)
DK (1) DK0805807T3 (da)
ES (1) ES2137554T3 (da)
GR (1) GR3031295T3 (da)
NZ (1) NZ297320A (da)
WO (1) WO1996022985A1 (da)
ZA (1) ZA96528B (da)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023072A1 (en) * 1998-10-20 2000-04-27 Omeros Medical Systems, Inc. Irrigation solution containing mapk inhibitors and their use for treating pain and inflammation
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US20020028798A1 (en) * 1995-12-12 2002-03-07 Omeros Medical Systems Irrigation solution and method for inhibition of pain and inflammation
JP2000508335A (ja) * 1996-05-30 2000-07-04 メルク エンド カンパニー インコーポレーテッド 癌の治療方法
AU5610398A (en) * 1997-02-28 1998-09-18 Warner-Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
US6007991A (en) * 1997-03-28 1999-12-28 The Research Foundation Of Suny Antisense oligonucleotides for mitogen-activated protein kinases as therapy for cancer
EP0972019A1 (en) 1997-03-28 2000-01-19 The Research Foundation Of State University Of New York Antisense oligonucleotides for mitogen-activated protein kinases as therapy for breast cancer
ATE344791T1 (de) * 1997-07-01 2006-11-15 Warner Lambert Co 2-(4-brom or 4-iod phenylamino)benzoesäurederivate und ihre anwendung als mek-inhibitoren
US6506798B1 (en) 1997-07-01 2003-01-14 Warner-Lambert Company 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
HUP0003731A3 (en) * 1997-07-01 2002-11-28 Warner Lambert Co 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors
US6310060B1 (en) 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
US6821963B2 (en) 1997-07-01 2004-11-23 Warner-Lambert Company 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
US6319955B1 (en) 1998-01-06 2001-11-20 The General Hospital Corporation Use of MEK1 inhibitors as protective agents against damage due to ischemia
WO1999034792A1 (en) * 1998-01-06 1999-07-15 The General Hospital Corporation Use of mek1 inhibitors as protective agents against damage due to ischemia
US6098631A (en) * 1998-01-21 2000-08-08 The Regents Of The University Of Michigan Compositions and methods for treating autoimmune disease
EP2311495B1 (en) * 1998-03-24 2014-09-24 Chugai Seiyaku Kabushiki Kaisha Vascularization inhibitors
US7354894B2 (en) * 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US20030219427A1 (en) * 1998-08-18 2003-11-27 Allen Hamish J. TPL-2/COT kinase and methods of use
US6846799B1 (en) 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
WO2000035435A1 (en) * 1998-12-15 2000-06-22 Warner-Lambert Company Use of a mek inhibitor for preventing transplant rejection
JP2002532415A (ja) * 1998-12-16 2002-10-02 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤による関節炎の治療
WO2000040235A2 (en) * 1999-01-07 2000-07-13 Warner-Lambert Company Treatment of asthma with mek inhibitors
ES2251851T3 (es) * 1999-01-13 2006-05-01 Warner-Lambert Company Llc Acidos sulfohidroxamicos y sulfohidroxamatos y su uso com inhibidores mek.
CA2348236A1 (en) * 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
WO2000042003A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
NZ513433A (en) 1999-01-13 2003-05-30 Warner Lambert Co Benzoheterocycles, their use as MEK inhibitors and use in treating proliferative diseases such as cancer
CA2355374A1 (en) * 1999-01-13 2000-07-20 Warner-Lambert Company 1-heterocycle substituted diarylamines
WO2000050030A1 (en) * 1999-02-25 2000-08-31 Ted Ebendal New use
GB9920908D0 (en) 1999-09-03 1999-11-10 Indena Spa Chalcone coumarins
GB9920910D0 (en) * 1999-09-03 1999-11-10 Indena Spa Novel chalcones
US7001905B2 (en) * 2000-03-15 2006-02-21 Warner-Lambert Company Substituted diarylamines as MEK inhibitors
US20020054869A1 (en) 2000-09-01 2002-05-09 Han-Mo Koo Inhibition of mitogen-activated protein kinase (MAPK) pathway: a selective therapeutic strategy against melanoma
EP1420778B1 (en) * 2001-03-06 2006-11-22 Dorian Bevec Use of mek inhibitors for treating virus induced hemorrhagic shock or fever
EP1409656A4 (en) * 2001-03-12 2005-01-12 Darley Pharmaceuticals Ltd SCREENING OF PHEROMONAL COMPOUNDS OF NON-STEROID AND NON-PEPTIDE INVERTEBRATE HAVING ACTIVITY MODULATING MITOGEN-ACTIVATED PROTEIN KINASE
US6806293B1 (en) * 2001-03-12 2004-10-19 Darley Pharmaceuticals Ltd Use of pheromone compounds having MAP kinase modulating activity
WO2002076496A1 (en) * 2001-03-22 2002-10-03 Van Andel Institute Anthrax lethal factor inhibits tumor growth and angiogenesis
NZ518726A (en) * 2001-05-09 2004-06-25 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
KR20020096367A (ko) * 2001-06-19 2002-12-31 주식회사 티지 바이오텍 관절염 예방 또는 치료제 및 그것의 스크리닝 방법
KR20020096368A (ko) * 2001-06-19 2002-12-31 주식회사 티지 바이오텍 연골세포의 분화촉진, 연골세포의 탈분화 억제 또는탈분화된 연골세포의 재분화 촉진제, 그것의 스크리닝방법 및 그것을 이용한 연골세포의 제조방법
WO2003062191A1 (en) * 2002-01-23 2003-07-31 Warner-Lambert Company Llc N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
DOP2003000556A (es) * 2002-01-23 2003-10-31 Warner Lambert Co Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
AU2003222221A1 (en) * 2002-02-15 2004-10-25 The General Hospital Corporation Map-kinase inhibitors as regulators of tumour-associated antigen expression
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
PL401637A1 (pl) 2002-03-13 2013-05-27 Array Biopharma Inc. N3 alkilowane pochodne benzimidazolu jako inhibitory MEK
PA8569201A1 (es) * 2002-03-13 2004-05-21 Array Biopharma Inc "derivados de bencimidazol n3 alquilado como inhibidores de mek" "n3 alkylated benzimimidazole derivatives as mek inhibitors"
JP2006516117A (ja) * 2002-11-21 2006-06-22 ジェネンテック・インコーポレーテッド 抗ＥｒｂＢ２抗体を用いた非悪性疾病または疾患の治療
ES2324165T3 (es) * 2003-02-26 2009-07-31 Kowa Co., Ltd. Tratamiento de la dermatitis alergica de contacto.
US20050049276A1 (en) * 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
ATE442847T1 (de) * 2003-07-24 2009-10-15 Warner Lambert Co Benzimidazol-derivate als mek-hemmer
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7517994B2 (en) * 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7732616B2 (en) * 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
WO2005051302A2 (en) * 2003-11-19 2005-06-09 Array Biopharma Inc. Bicyclic inhibitors of mek and methods of use thereof
CN1882347A (zh) * 2003-11-21 2006-12-20 阿雷生物药品公司 Akt蛋白激酶抑制剂
EP1699477A2 (en) * 2003-12-11 2006-09-13 Theravance, Inc. Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
SI1802579T1 (sl) 2004-10-20 2014-03-31 Merck Serono Sa Derivati 3-arilaminopiridina
EP1838675A1 (en) * 2004-11-24 2007-10-03 Laboratoires Serono S.A. Novel 4-arylamino pyridone derivatives as mek inhibitors for the treatment of hyperproliferative disorders
EP1967516B1 (en) * 2005-05-18 2009-11-04 Array Biopharma, Inc. 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as MEK inhibitors for the treatment of hyperproliferative diseases
US20080199449A1 (en) * 2005-08-12 2008-08-21 The General Hospital Corporation Methods and Compositions for Use in Treating Vascular Diseases and Conditions
EP1953148B1 (en) 2005-10-28 2012-02-29 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof
BRPI0713555A2 (pt) * 2006-07-06 2012-03-20 Array Biopharma, Inc. ciclopenta [d] pirimidinas como inibidores de akt protéina cinase
EP2054418B1 (en) 2006-07-06 2011-11-09 Array Biopharma Inc. Dihydrothieno pyrimidines as akt protein kinase inhibitors
US8063050B2 (en) * 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8329701B2 (en) 2006-07-06 2012-12-11 Array Biopharma Inc. Dihydrofuro pyrimidines as AKT protein kinase inhibitors
CA2692506C (en) * 2007-07-05 2015-11-24 Array Biopharma Inc. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
AU2008272830B8 (en) 2007-07-05 2013-12-12 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
EP2182801A4 (en) * 2007-07-31 2011-04-13 Limerick Biopharma Inc COMPOSITIONS OF PYRONE ANALOGS AND METHODS
US20090062255A1 (en) * 2007-08-17 2009-03-05 Thallion Pharmaceuticals Inc. Tumor-targeting evaluation methodology and compounds related thereto
MX2010007546A (es) * 2008-01-09 2010-09-30 Array Biopharma Inc Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteína quinasa.
NZ586346A (en) * 2008-01-09 2012-02-24 Array Biopharma Inc Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
CA2732828C (en) * 2008-08-04 2017-06-13 Merck Patent Gmbh Phenylamino isonicotinamide compounds
WO2010051933A2 (en) 2008-11-10 2010-05-14 Bayer Schering Pharma Aktiengesellschaft Substituted sulphonamido phenoxybenzamides
CA2777430A1 (en) 2009-10-21 2011-04-28 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
WO2011047796A1 (en) 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted halophenoxybenzamide derivatives
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
WO2012019113A2 (en) 2010-08-05 2012-02-09 Case Western Reserve University Inhibitors of erk for developmental disorders of neuronal connectivity
WO2012055953A1 (en) 2010-10-29 2012-05-03 Bayer Pharma Aktiengesellschaft Substituted phenoxypyridines
CN103841976A (zh) 2011-04-01 2014-06-04 基因泰克公司 Akt和mek抑制剂化合物的组合及其使用方法
HUE036513T2 (hu) 2011-04-01 2018-07-30 Genentech Inc AKT inhibitor vegyület és abirateron kombinációja terápiás kezelésekben való alkalmazásra
EP2714039A1 (en) * 2011-05-23 2014-04-09 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mek inhibitors
ES2597052T3 (es) 2011-05-25 2017-01-13 Université Paris Descartes Inhibidores de ERK para su uso en el tratamiento de atrofia muscular espinal
WO2013067162A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
CA2853806C (en) 2011-11-02 2020-07-14 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
AU2012339679A1 (en) 2011-11-14 2014-06-12 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with BRAF inhibitors
EP2958992A1 (en) 2013-02-22 2015-12-30 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
WO2015038704A1 (en) 2013-09-11 2015-03-19 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Compositions for preparing cardiomyocytes
EP3094736A4 (en) 2014-01-14 2017-10-25 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
WO2015164228A1 (en) 2014-04-21 2015-10-29 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
US20170248603A1 (en) 2014-10-06 2017-08-31 Dana-Farber Cancer Institute, Inc. Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response
MA41866A (fr) 2015-03-31 2018-02-06 Massachusetts Gen Hospital Molécules à auto-assemblage pour l'administration ciblée de médicaments
WO2018146253A1 (en) 2017-02-10 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
WO2020051370A1 (en) * 2018-09-06 2020-03-12 North Carolina Central University Discovery of novel potent inhibitors of the map3k mekk2
WO2021043724A1 (en) 2019-09-02 2021-03-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of pyrvinium for the treatment of a ras pathway mutated acute myeloid leukemia
TW202342018A (zh) 2022-03-04 2023-11-01 美商奇奈特生物製藥公司 Mek激酶抑制劑

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3816466A (en) * 1971-12-22 1974-06-11 Warner Lambert Co Flavanoid ring systems
US5116954A (en) * 1988-04-06 1992-05-26 Lipha, Lyonnaise Industrielle Pharmaceutique Pharmaceutically useful flavonoic compounds containing at least one substituent on the benzopyranone ring moiety
JPH05286962A (ja) * 1992-02-14 1993-11-02 Kyowa Hakko Kogyo Co Ltd ５−アミノフラボン誘導体

Also Published As

Publication number Publication date
US5525625A (en) 1996-06-11
EP0805807B1 (en) 1999-07-07
CA2208075A1 (en) 1996-08-01
EP0805807A1 (en) 1997-11-12
JPH10512878A (ja) 1998-12-08
MX9704649A (es) 1997-09-30
AU4245696A (en) 1996-08-14
NZ297320A (en) 1999-05-28
DE69510696T2 (de) 1999-12-23
GR3031295T3 (en) 1999-12-31
ATE181913T1 (de) 1999-07-15
ES2137554T3 (es) 1999-12-16
ZA96528B (en) 1996-08-15
WO1996022985A1 (en) 1996-08-01
AU690400B2 (en) 1998-04-23
DE69510696D1 (de) 1999-08-12

Similar Documents

Publication Publication Date Title
DK0805807T3 (da) 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-(1)-benzopyran til behandling af proliferative sygdomme
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
PL336788A1 (en) Probucol monoesters in treating circulatory system and inflammatory diseases
MY121548A (en) Compounds and methods for the treatment of cancer
ATE288749T1 (de) Verwendung von kannabidiol als entzündunghemmende mittel
ATE282425T1 (de) Verfahren zur behandlung von endothelialen verletzungen
DK0786991T3 (da) Polyaminforbindelsre til behandling af proliferative karsygdomme
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
ATE246924T1 (de) Neue therapeutische verwendung von nicergoline
IT1289154B1 (it) Derivati di isoflavone loro preparazione e loro impiego terapeutico
DK0869813T3 (da) Anvendelse af beta-interferoner til behandling af restenose
NO962221D0 (no) Anvendelse av dimeticon for behandling av konstipasjon
DE59908268D1 (de) Khellin-zubereitung und deren verwendung zur topischen therapie
NO984198L (no) FremgangsmÕte for behandling av aggresjon
SE9301606D0 (sv) Composition for the treatment of impaired hair growth
ATE225181T1 (de) Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen
UA10928C2 (uk) Спосіб профілактики гіперхолестериhемії
DE69711422D1 (de) Verwendung von (r)-verapamil als medizin zur behandlung von angina
DE69831336D1 (de) Tazaroten und uvb-phototherapie zur behandlung von psoriasis
DK1017377T3 (da) Anvendelse af 6,7-substituerede 2-aminotetraliner til behandling af af cytokin fremkaldte inflammatoriske tilstande
UA8280A (uk) Спосіб лікування псоріазу
ATE247467T1 (de) Neue therapeutische verwendung von 1,6-dimethyl- 8beta-hydroxymethyl-10alpha-methoxyergolin